Serum Ang-2, bFGF, CCL2 levels at baseline were associated with frequency of adverse events: high Ang-2 levels were associated with T-BIL increase ≥ grade 3 (P = 0.010); high bFGF levels were associated with AST (P = 0.004) or ALT (P = 0.012) increase ≥ grade 3; low bFGF levels were associated with HT ≥ grade 3 (P = 0.008) and low CCL2 levels were associated with HFSR ≥ grade 2 (P = 0.030) (Table 3). This evidence concerns the gene CCL2 and hematocrit.